TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vitamin D Supplementation on Antimycobacterial Immunity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult~* Tuberculosis (TB) contact or TB patient~Exclusion Criteria:~* Pregnancy~* Breastfeeding~* Hyperparathyroidism~* Sarcoidosis~* Renal failure~* HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intervention for IPV Perinatal Women- RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant or postpartum women (up to 6 months after delivery)~* Age 18 or older~* Seeking mental health treatment at The Center for Women's Behavioral Health (WBH) at Women and Infants Hospital (WIH)~* Endorsed any IPV during the past 12 months as measured by the Woman Abuse Screening Tool (WAST)~Exclusion Criteria:~* Inability to provide informed consent (e.g., due to psychosis, intoxication, or other clear cognitive impairment)~* Inability to understand English (understand the consent form when read aloud and assessments that are narrated by computer)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ROSE Program (Type: EXPERIMENTAL): Participants received a 35-40-minute intervention on the Tablet PC and an in-person 10-15-minute booster session conducted by interventionists within a month after the intervention. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
- Control Condition (Type: NO_INTERVENTION): Control Condition consisted of a series of questions regarding television show preferences and then viewed a brief series of videos of popular entertainers/shows, with subsequent requests for ratings of subjective preference. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of birch and/or timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years~* Body mass index (BMI) between 19 and 30 kg/ m2 and a weight between 50 and 100 kg~* No clinically relevant abnormal findings~Exclusion Criteria:~* Acute illness which requires medical intervention~* Definite or suspected personal history of adverse drug reactions or drug hypersensitivity~* Clinical relevant disease or disorder (past or present)~* A history of asthma

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria~* Levodopa-responsive participants who demonstrate some identifiable 'on response,' established by Investigator observation~* Demonstrate severe motor fluctuations in spite of individually optimized treatment and where therapy options are indicated~Exclusion Criteria:~* Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism~* Undergone surgery for the treatment of PD~* Contraindications to levodopa~* Subjects with any neurological deficit that may interfere with the study assessments

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules (Type: EXPERIMENTAL): Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
- Placebo Gel + Levodopa-Carbidopa Capsules (Type: ACTIVE_COMPARATOR): Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Korean Life-Style Modification Effects on Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult age \>20~2. If the subject not taken antihypertension, SBP and DBP must be the following result.~   SBP: 120\~159 mmHg , DBP: 80-99 mmHg~3. If the subject taken antihypertension, SBP and DBP must be the following result.~   SBP: 140-159mmHg ,DBP: 90-99 mmHg~4. BMI 18.5kg/m²\~44kg/m²~5. Patients voluntarily agreed to participate in this study~6. Non-pregnant women, Non-breastfeeding women, women of childbearing age must be negative in HCG result.~(not taking an oral contraceptive)~Exclusion Criteria:~1. If the subject not taken antihypertension, SBP and DBP must be the following result.~   * 120\>SBP\>159 mmHg, 80\>DBP\>99 mmHg~2. If the subject taken antihypertension, the number of three or more antihypertensive~3. If the subject taken antihypertension, SBP and DBP must be the following result.~   * 140\>SBP\>159 mmHg, 90\>DBP\>99 mmHg~4. having the target organ disease, the following disease.~   * Heart disease: Lt.venricular hyperplasia, Angina, MI, Coronary revascularization, Heart failure~  * Brain disease: Stroke, TIA, Dementia~  * Kidney disease:~  * Pheripheral artery disease~  * Retinopathy Disease~5. Cancer, Liver disease~6. Regular drinking alcohol above 14 cup of during 1 week.~7. Pregnant women, Women of childbearing age tested positive in HCG result.~8. Pregnant women, Breastfeeding women~9. screening test result CS~10. illiteracy, a foreigner, the person who can't read the consent~11. the person who had participated other study in 3 months.~12. the person who inappropriate to participate

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- general management (Type: ACTIVE_COMPARATOR): None
- The treatment group1 (Type: EXPERIMENTAL): Korean DASH diet with sodium reduction intervention
- The treatment group2 (Type: EXPERIMENTAL): Korean DASH diet with sodium reduction intervention and excersize intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brain Effects of Escitalopram and Citalopram Using fMRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male aged 21 to 50 years.~* Capable of providing informed consent.~* Has an established residence and phone.~Exclusion Criteria:~* Meets DSM-IV criteria for an Axis I or II disorder.~* History of substance dependence or abuse within the past month.~* Use of NSAID's, beta blockers, calcium channel blockers, antidepressants, antipsychotic medications, lithium or other medication which in the opinion of the investigator would alter vascular responsivity.~* Regular use of sedative hypnotic or narcotic medication, or other medication that might affect the individual's perception of visual stimuli.~* History of cataracts or significant visual impairment.~* A medical condition, which in the opinion of the investigator is likely to affect the individual's perception of the visual stimuli or vascular response.~* Participation in a research protocol that included administration of medication within the past 3 months.~* Cigarette smoking.

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): One week of escitalopram at 10 mg followed by one week at 20 mg in healthy volunteers.
- Citalopram (Type: ACTIVE_COMPARATOR): One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.
- Placebo (Type: PLACEBO_COMPARATOR): Two weeks of placebo in healthy volunteers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Japanese Participants With Moderate-to-Severe Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men must agree to use a reliable method of birth control during the study~* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~* Candidates for phototherapy and/or systemic therapy~* Present with chronic psoriasis based on a confirmed psoriasis diagnosis for at least 6 months prior to enrollment~* At least 10% Body Surface Area (BSA) of Psoriasis at screening and at enrollment for participants with plaque psoriasis~* Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at enrollment for participants with plaque psoriasis~Exclusion Criteria:~* History of drug-induced psoriasis~* Concurrent or recent use of any biologic agent~* Received systemic psoriasis therapy \[such as psoralen and ultraviolet A (PUVA) light therapy\] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment for participants with plaque psoriasis~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study~* Have participated in any study with interleukin-17(IL-17) antagonists, including ixekizumab~* Serious disorder or illness other than psoriasis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women~* Clinically significant flare of psoriasis during the 12 weeks prior to enrollment for participants with plaque psoriasis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 80 mg ixekizumab (Type: EXPERIMENTAL): Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ruboxistaurin on Small Fiber Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have Type 1 or Type 2 diabetes mellitus~* Patients must have bilateral sensorimotor distal peripheral neuropathy attributable to diabetes mellitus~* Patients must have blood glucose control measured as HbA1c=\<11%~* Patients must be 18 years of age or older.~* Patients must be able to return to all follow-up visits~Exclusion Criteria:~* Patients must not have symptoms of diabetic peripheral neuropathy that cannot be distinguished from other etiologies~* Patients must not have a neurologic disease or neuropathy from a cause other than diabetes mellitus that would interfere with correct evaluation of symptomatic peripheral neuropathy.~* Patient currently has uncontrolled high blood pressure~* You have other medical problems that your doctor feels would make it unsafe for you to participate in this study such as liver or kidney problems~* You are a woman of childbearing age and unwilling or unable to use effective contraceptive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed ICF (Informed Consent Form)~2. Subject-reported history of Drye Eye Disease (DED) in both eyes~3. Ability and willingness to follow instructions, including participation in all study assessments and visits~Exclusion Criteria:~1. clinically significant slit lamp findings or abnormal lid anatomy at screening, including eye trauma, pterygium, active blepharitis, and active lid margin inflammation;~2. Stevens-Johnson syndrome or other severe systemic autoimmune diseases;~3. underwent LipiFlow procedure or intention pulsed light therapy within 6 months before baseline, or received Meibomian gland massage treatment within 2 weeks before baseline;~4. received or removed permanent lacrimal plug within 3 months before baseline;~5. DED secondary to scarring, radiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells;~6. ocular or periocular malignancy;~7. active ocular allergies, or allergy to the study drug or its components;~8. ongoing ocular or systemic infection;~9. use of contact lenses within 1 month before screening;~10. intraocular surgery or ocular laser surgery within 6 months before enrollment;~11. uncontrolled systemic disease or history of herpetic keratitis;~12. use of topical steroids, topical cyclosporine, lifitegrast, serum tears, or topical anti-glaucoma medication within 60 days before screening;~13. used any known oral drugs that could have caused eye dryness within 1 month before screening;~14. participated in or were participating in other clinical trials drugs or device within 60 days before baseline;~15. inappropriate to participate for other reasons judged by the investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group A: SHR8058 eye drops (Type: EXPERIMENTAL): None
- Treatment group B: saline eye drops (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia, schizoaffective disorder (depressed type), or schizophreniform disorder~* First major episode of psychotic symptoms occurred within 2 years prior to study entry~Exclusion Criteria:~* Neurological disorder or injury (e.g., encephalitis, epilepsy, traumatic brain injury)~* Mental retardation (e.g., premorbid intelligence quotient (IQ) less than 70)~* Significant alcohol or substance use during last 6 months~* Unable to complete research measures in English~* Any condition that may make risperidone use medically inadvisable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cog Remediation, risperidone injection (Type: EXPERIMENTAL): Participants will receive cognitive remediation training plus risperidone, administered via injection.
- Healthy Behavior Training, risperidone injection (Type: ACTIVE_COMPARATOR): Participants will receive health behavior training plus risperidone, administered via injection.
- Cog Remediation, oral risperidone (Type: EXPERIMENTAL): Participants will receive cognitive remediation training plus risperidone administered orally.
- Healthy Behavior Training, oral risperidone (Type: ACTIVE_COMPARATOR): Participants will receive health behavior training plus risperidone administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diabetic foot ulcer~* \< = 80 years old~* diabetic foot ulcer wegnar 2-4 stage~Exclusion Criteria:~* Wagner grade 0,1 and grade 5~* severe coronary, cerebral, renal vascular as well as severe liver diseases, malignant neoplasms~* bleeding individuals~* \> 80 years old~* heart failure (NYHA 3,4)~* cancer

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- continuous intra-femoral thrombolysis group (Type: EXPERIMENTAL): Continuous intra-femoral injection urokinase was taken by a mini-pump in 100 diabetic foot ulcers (Wegnar 2 \~ 4 stage) for 7 - 9 days.Then they receive conventional therapy. The healing rate of foot ulcers is observed during hospitalization period. At 1, 4 and 8 year during follow up, the recurrence rate of diabetic foot ulcers are observed.
- conventional therapy group (Type: ACTIVE_COMPARATOR): Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Milk in Life Conditions (MiLC): Bacterial Composition of Human Milk Pumped and Stored in Real-Life Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lactating women over the age of 18 years~* Self-reported as healthy women and infants~* Use an electric breast pump~* Confident of ability to donate 1 oz of milk from one breast during each of two consecutive pumping sessions where pumping sessions are 3 hours (+/- 30 minutes) apart and between 0700-1100 hours.~* Able to store donated milk at home for 30 days~* Have infants who do not consume formula or only consume formula episodically as long as the most recent formula-feeding occurred \> 2 weeks before the day milk is pumped for this study.~Exclusion Criteria:~* Not confident of ability to donate 1 oz of milk from one breast during each of two consecutive pumping sessions, 3 hours (+/- 30 minutes) apart and between the hours of 0700-1100 hours.~* Infant consumption of formula in the past 2 weeks~* Current indication of breast infection (e.g., breast pain, discomfort, lumps, mastitis with fever, red streaks, or hard red portions of the breast)~* Breast pain that the woman does not consider normal for lactation/breastfeeding~* Signs/symptoms of acute illness in woman or infant in past 7 days including fever (rectal or temporal temperature ≥99.5 F), dark green nasal discharge, diarrhea (abrupt onset of 3 or more excessively loose stools in one day), vomiting (where infant vomiting is not associated with feeding), or severe cough.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sterile pump set-up first (Type: EXPERIMENTAL): Participants will pump with sterile pump set-ups first. Approximately 3 hours later, participants will pump with their own pump set-ups.
- Mother's Own pump set-up first (Type: EXPERIMENTAL): Participants will pump with their own pump set-ups first. Approximately 3 hours later, participants will pump with sterile pump set-ups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete